OTCMKTS:OXBDF - Oxford Biomedica Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$17.98
▼ -0.02 (-0.11%)

This chart shows the closing price for OXBDF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXBDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXBDF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.98.

This chart shows the closing price for OXBDF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Oxford Biomedica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/22/2021HC WainwrightReiterated RatingBuy
7/7/2021Panmure GordonUpgradeHold ➝ Buy
6/21/2021Royal Bank of CanadaReiterated RatingOutperform
5/25/2021Royal Bank of CanadaReiterated RatingOutperform
5/14/2021InvestecUpgradeSell ➝ Hold
11/2/2020HC WainwrightReiterated RatingBuy
9/17/2020HC WainwrightReiterated RatingBuy
9/8/2020Royal Bank of CanadaReiterated RatingBuy
9/2/2020HC WainwrightReiterated RatingBuy
8/4/2020HC WainwrightReiterated RatingBuy
7/28/2020Liberum CapitalReiterated RatingBuy
7/28/2020Peel HuntReiterated RatingBuy
7/27/2020Royal Bank of CanadaInitiated CoverageOutperform
5/6/2020HC WainwrightReiterated RatingBuy
12/19/2019HC WainwrightReiterated RatingBuy
9/4/2019HC WainwrightReiterated RatingBuy$14.50
5/28/2019HC WainwrightReiterated RatingBuy$14.50
10/31/2017HC WainwrightReiterated RatingBuy
12/5/2016Roth CapitalReiterated RatingBuy
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $17.98
Low: $17.98
High: $17.98

50 Day Range

MA: $20.33
Low: $17.98
High: $22.85

52 Week Range

Now: $17.98
Low: $11.00
High: $22.86

Volume

201 shs

Average Volume

2,125 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following sell-side analysts have issued stock ratings on Oxford Biomedica in the last year: HC Wainwright, Investec, Panmure Gordon, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for OXBDF.

What is the current price target for Oxford Biomedica?

0 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oxford Biomedica in the next year.
View the latest price targets for OXBDF.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OXBDF will outperform the market and that investors should add to their positions of Oxford Biomedica.
View the latest ratings for OXBDF.

What other companies compete with Oxford Biomedica?

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company's listed phone number is 44-18-6578-3000. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk.